SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- Dubai Stock Market Fear Has 'Legs': Dennis Gartman

MORE HEADLINES

» Markets | Economy | Companies

- Dubai Spooks Investors But May Bring Buying Opportunity

PHARMA'S MARKET VIDEO

» More

Sebelius on Vaccines

24 Nov 2009

Discussing whether a new $487M investment from the government will help speed up the production of the most important vaccines, with Kathy Sebelius, Health & Human Services secretary and CNBC's Mike Huckman.

The New Formula for Faster Vaccines

24 Nov 2009

Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are faster, better and cheaper to make than egg-based methods, reports CNBC's Mike Huckman.

Novartis Opens 1st US Plant for Flu Vaccine

24 Nov 2009

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

May.21

4:41 PM ET

Wednesday, 21 May 2008

Icahn To Go Behind-The-Scenes At Biogen Idec

Posted By:Mike Huckman

Topics:Carl Icahn | Mergers & Acquisitions | Pharmaceuticals

Sectors:Health Care Equipment and Services | Health Care | Pharmaceuticals

Companies:Yahoo! Inc | Hewlett-Packard Co | Biogen Idec Inc

I got back sooner than I expected from my assignment and when the plane landed and I fired up my BlackBerry an email from Bear Stearns biotech analyst Mark Schoenebaum stuck out from the bunch that came flooding in.

Yeah, Schoenebaum is still there. On a recent conference call with clients that he invited me to listen to, Schoenebaum announced that he'll soon be working at another, as yet unidentified, firm. And as is apparently his quirky way, he played a recording of "Taps" at the start of the call because he thought might be his last at Bear. It wasn't. Anyway, I digress.

So, Carl Icahn is grabbing headlines this week over his new battle with Yahoo [YHOO Loading... () ] and how Boone Pickens is backing him up now, too. But Icahn has his finger in a lot of pies. He's still in a proxy fight with Biogen Idec [BIIB Loading... () ] where he's trying to get his people on the Board at the upcoming shareholder meeting on June 19th. But in the meantime, Icahn is trying to find out what went on inside the biotech company when, at his urging, it put itself on the market last year, the stock soared, and then came crashing back to earth when BIIB announced it couldn't find a buyer.

(BIIB)

Loading... (%)

To that end (and props to Schoenebaum for staying on top of this), Icahn's lawyers went into a Delaware court yesterday to get Biogen Idec to turn over internal documents and communications from the auction process. And Icahn won.

According to the transcript, Delaware Chancery Court Judge William Chandler, who I covered several years ago when he oversaw the fight between Walter Hewlett and Carly Fiorina over HP's [HPQ Loading... () ] acquisition of Compaq, said he comes down "slightly" in favor of Icahn. He ruled from the bench that Icahn has a right to see the documents to "demonstrate unequivocally...whether there was some deliberate effort here to manipulate the process or to create a process that was doomed to fail from the outset."

Judge Chandler also ordered Icahn to keep the stuff confidential and/or to come to some kind of agreement with the company about what should stay top secret and what can be made public--(er, leaked to the media?). But if they can't come to terms on that the judge wants them back in court.

In a research note to clients this afternoon, Schoenebaum writes, "If, indeed, a 'smoking gun' document exists, yesterday's court decision should help Icahn's team obtain it. However, even if such a document exists, it is not certain that the judge would allow it to be made public. In order to broadly influence the shareholder vote, we believe it would need to be made public well ahead of the June 19th shareholder meeting.

Thus, we believe the Judge's decision has only modestly changed the probability that Icahn's director slate is nominated." Schoenebaum also points out that Institutional Shareholder Services hasn't made a call yet on Icahn's proxy fight and that ISS' recommendation could also be a deciding factor. Bear Stearns says it makes a market in BIIB and/or is associated with a market maker.

Between Yahoo and Biogen Idec you might say the billionaire activist investor has his hands full. But another one of Icahn's babies will also be making news over the next couple of weeks. At the end of this month ImClone Systems [IMCL Loading... () ] (Icahn is Chairman) will be the headliner at this year's American Society of Clinical Oncology meeting where IMCL will be releasing highly anticipated test results on Erbitux for lung cancer. Doctors, analysts and investors are anxious to hear how much time the drug might have added to patients' lives and about the severity or frequency of side effects.